Earnings ·
Relmada Therapeutics reported a net loss of $12.9 million ($0.11 per share) for the quarter ended June 30, 2026, with…
RLMDRelmada Therapeutics, Inc.
Relmada Therapeutics reported a net loss of $12.9 million ($0.11 per share) for the quarter ended June 30, 2026, with research and development expenses rising to $8.4 million. The company holds $217.7 million in cash and short-term investments as of June 30, 2026, which management expects will fund operations through 2029, including the completion of the Phase 3 RESCUE program for NDV-01. Relmada plans to file Investigational New Drug applications for both NDV-01 and sepranolone by year-end 2026, with Phase 3 and Phase 2 trials expected to initiate upon clearance. Additionally, Bipin Dalmia was appointed Chief Business Officer, and the company was added to the Russell 2000 and Russell 3000 indexes effective June 26, 2026. Relmada Therapeutics is a clinical-stage biotechnology company developing therapies for oncology and central nervous system disorders.